Submissions for variant NM_000260.4(MYO7A):c.401T>A (p.Ile134Asn)

gnomAD frequency: 0.00003  dbSNP: rs111033181

Total submissions: 7

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
ClinGen Hearing Loss Variant Curation Expert Panel	RCV001775073	SCV002011862	likely pathogenic	Usher syndrome	2020-11-02	reviewed by expert panel	curation	The allele frequency of the c.401T>A (p.Ile134Asn) variant in the MYO7A gene is 0.0062% (7/112888) of European (non-Finnish) chromosomes by gnomAD, which is a low enough frequency to apply PM2 based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss. This variant has been detected in 5 probands with Usher syndrome. For 2 of those probands, pathogenic variants (c.19-1G>A and Gly214Arg) were observed in trans, and in the other 3 probands, a pathogenic variant was observed with unknown phase (PM3_Strong, PMIDs: 25468891, 26969326, Partners LMM Internal Data ClinVar SCV000059786.6). The variant has been reported to segregate with hearing loss in one affected family member (PP1, Partners LMM Internal Data ClinVar SCV000059786.6). The REVEL computational prediction tool produced a score of 0.938, which is above the threshold necessary to apply PP3. At least one patient with this variant displayed features of sensorineural hearing loss and retinitis pigmentosa, which are consistent for Usher syndrome, a condition highly specific for MYO7A (PP4, Partners LMM Internal Data ClinVar SCV000059786.6). In summary, this variant meets criteria to be classified as likely pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied as specified by the Hearing Loss Expert Panel (PM3_Strong, PM2, PP1, PP3, PP4).
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000036134	SCV000059786	likely pathogenic	Rare genetic deafness	2011-03-25	criteria provided, single submitter	clinical testing	The Ile134Asn variant in MYO7A has been reported in one proband with Usher syndr ome Type I and was absent in 172 control chromosomes (Bharadwaj 2000). We have a lso observed this variant in another patient with Usher syndrome with a pathogen ic variant on the other allele. In addition, this residue is highly conserved ac ross species and computational analyses (biochemical amino acid properties, homo logy, PolyPhen2, SIFT) suggest that the variant may impact the protein. In summa ry, this data suggests this variant is likely pathogenic.
Counsyl	RCV000673536	SCV000798748	likely pathogenic	Autosomal recessive nonsyndromic hearing loss 2; Usher syndrome type 1	2018-03-23	criteria provided, single submitter	clinical testing
Blueprint Genetics	RCV001074683	SCV001240276	pathogenic	Retinal dystrophy	2019-03-21	criteria provided, single submitter	clinical testing
Invitae	RCV001231996	SCV001404537	pathogenic	not provided	2024-01-04	criteria provided, single submitter	clinical testing	This sequence change replaces isoleucine, which is neutral and non-polar, with asparagine, which is neutral and polar, at codon 134 of the MYO7A protein (p.Ile134Asn). This variant is present in population databases (rs111033181, gnomAD 0.006%). This missense change has been observed in individuals with Usher syndrome (PMID: 25468891, 26969326; Invitae). ClinVar contains an entry for this variant (Variation ID: 43230). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MYO7A protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic.
Illumina Laboratory Services, Illumina	RCV001249698	SCV001423720	uncertain significance	MYO7A-Related Disorders	2019-11-01	criteria provided, single submitter	clinical testing	The MYO7A c.401T>A (p.Ile134Asn) variant is a missense variant which has been reported in two studies in which it has been identified in a compound heterozygous state in two patients with Usher syndrome (Bujakowska et al. 2014; Sloan-Heggen et al. 2016). The p.Ile134Asn variant is reported at a frequency of 0.000062 in the European (non-Finnish) population of the Genome Aggregation Database in a region of good sequence coverage, suggesting that it is a rare variant. The p.Ile134Asn variant is highly conserved through evolution, and in silico tools predict the variant to be damaging for the protein function. Functional studies for the variant were not performed. Based on the limited evidence and application of the ACMG criteria, the p.Ile134Asn variant is classified as a variant of unknown significance for MYO7A-related disorders.
GeneDx	RCV001231996	SCV001784239	likely pathogenic	not provided	2023-03-08	criteria provided, single submitter	clinical testing	Observed in multiple unrelated patients with Usher syndrome referred for genetic testing at GeneDx and in published literature (Sloan-Heggen et al., 2016; Wafa et al., 2021); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 10930322, 10094549, 26969326, 33089500, 26582918)